139 related articles for article (PubMed ID: 37609390)
1. Oral treatment with the all-d-peptide RD2 enhances cognition in aged beagle dogs - A model of sporadic Alzheimer's disease.
Kutzsche J; Schemmert S; Bujnicki T; Zafiu C; Halbgebauer S; Kraemer-Schulien V; Pils M; Blömeke L; Post J; Kulawik A; Jürgens D; Rossberg WM; Hümpel M; Bannach O; Otto M; Araujo JA; Willuweit A; Willbold D
Heliyon; 2023 Aug; 9(8):e18443. PubMed ID: 37609390
[TBL] [Abstract][Full Text] [Related]
2. Aβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer's Mice with Full-blown Pathology.
Schemmert S; Schartmann E; Zafiu C; Kass B; Hartwig S; Lehr S; Bannach O; Langen KJ; Shah NJ; Kutzsche J; Willuweit A; Willbold D
Mol Neurobiol; 2019 Mar; 56(3):2211-2223. PubMed ID: 30003517
[TBL] [Abstract][Full Text] [Related]
3. The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology.
van Groen T; Schemmert S; Brener O; Gremer L; Ziehm T; Tusche M; Nagel-Steger L; Kadish I; Schartmann E; Elfgen A; Jürgens D; Willuweit A; Kutzsche J; Willbold D
Sci Rep; 2017 Nov; 7(1):16275. PubMed ID: 29176708
[TBL] [Abstract][Full Text] [Related]
4. Deceleration of the neurodegenerative phenotype in pyroglutamate-Aβ accumulating transgenic mice by oral treatment with the Aβ oligomer eliminating compound RD2.
Schemmert S; Schartmann E; Honold D; Zafiu C; Ziehm T; Langen KJ; Shah NJ; Kutzsche J; Willuweit A; Willbold D
Neurobiol Dis; 2019 Apr; 124():36-45. PubMed ID: 30391539
[TBL] [Abstract][Full Text] [Related]
5. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.
Izzo NJ; Yuede CM; LaBarbera KM; Limegrover CS; Rehak C; Yurko R; Waybright L; Look G; Rishton G; Safferstein H; Hamby ME; Williams C; Sadlek K; Edwards HM; Davis CS; Grundman M; Schneider LS; DeKosky ST; Chelsky D; Pike I; Henstridge C; Blennow K; Zetterberg H; LeVine H; Spires-Jones TL; Cirrito JR; Catalano SM
Alzheimers Dement; 2021 Aug; 17(8):1365-1382. PubMed ID: 33559354
[TBL] [Abstract][Full Text] [Related]
6. Oral absorption enhancement of the amyloid-β oligomer eliminating compound RD2 by conjugation with folic acid.
Elfgen A; Santiago-Schübel B; Hupert M; Schemmert S; Schartmann E; Tusche M; Gering I; Zafiu C; Kutzsche J
Eur J Pharm Sci; 2021 Jan; 156():105581. PubMed ID: 33035662
[TBL] [Abstract][Full Text] [Related]
7. Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-β oligomers.
Elfgen A; Hupert M; Bochinsky K; Tusche M; González de San Román Martin E; Gering I; Sacchi S; Pollegioni L; Huesgen PF; Hartmann R; Santiago-Schübel B; Kutzsche J; Willbold D
Sci Rep; 2019 Apr; 9(1):5715. PubMed ID: 30952881
[TBL] [Abstract][Full Text] [Related]
8. Do We Need Anti-Prion Compounds to Treat Alzheimer's Disease?
Willbold D; Kutzsche J
Molecules; 2019 Jun; 24(12):. PubMed ID: 31208037
[TBL] [Abstract][Full Text] [Related]
9. Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer's Disease.
Kutzsche J; Schemmert S; Tusche M; Neddens J; Rabl R; Jürgens D; Brener O; Willuweit A; Hutter-Paier B; Willbold D
Molecules; 2017 Oct; 22(10):. PubMed ID: 28994710
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Pharmacodynamic Effect of a Blood-Brain Barrier-Crossing Fusion Protein Therapeutic for Alzheimer's Disease in Rat and Dog.
Lessard E; Rennie K; Haqqani A; Ling B; Whitfield J; Paradis A; Araujo J; Yoganathan N; Gillard J; Stanimirovic D; Chakravarthy B
Pharm Res; 2022 Jul; 39(7):1497-1507. PubMed ID: 35704250
[TBL] [Abstract][Full Text] [Related]
11. [Constructing Brain Aβ-Targeting Nanoparticles Loaded with EGCG for Treating Alzheimer's Disease in Mice].
Yang P; Guo Q; Xu ST; Sheng DY; Zhang QZ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Jul; 52(4):605-611. PubMed ID: 34323038
[TBL] [Abstract][Full Text] [Related]
12. A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease.
Luo J; Lee SH; VandeVrede L; Qin Z; Ben Aissa M; Larson J; Teich AF; Arancio O; D'Souza Y; Elharram A; Koster K; Tai LM; LaDu MJ; Bennett BM; Thatcher GR
Mol Neurodegener; 2016 Apr; 11():35. PubMed ID: 27129593
[TBL] [Abstract][Full Text] [Related]
13. Toward the Mode of Action of the Clinical Stage All-d-Enantiomeric Peptide RD2 on Aβ42 Aggregation.
Zhang T; Gering I; Kutzsche J; Nagel-Steger L; Willbold D
ACS Chem Neurosci; 2019 Dec; 10(12):4800-4809. PubMed ID: 31710458
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic Properties of a Novel D-Peptide Developed to be Therapeutically Active Against Toxic β-Amyloid Oligomers.
Leithold LH; Jiang N; Post J; Ziehm T; Schartmann E; Kutzsche J; Shah NJ; Breitkreutz J; Langen KJ; Willuweit A; Willbold D
Pharm Res; 2016 Feb; 33(2):328-36. PubMed ID: 26381279
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the
Willuweit A; Humpert S; Schöneck M; Endepols H; Burda N; Gremer L; Gering I; Kutzsche J; Shah NJ; Langen KJ; Neumaier B; Willbold D; Drzezga A
Eur J Pharm Sci; 2023 May; 184():106421. PubMed ID: 36889654
[TBL] [Abstract][Full Text] [Related]
16. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
[TBL] [Abstract][Full Text] [Related]
17. Polyunsaturated Fatty Acid Composition of Cerebrospinal Fluid Fractions Shows Their Contribution to Cognitive Resilience of a Pre-symptomatic Alzheimer's Disease Cohort.
Fonteh AN; Cipolla M; Chiang AJ; Edminster SP; Arakaki X; Harrington MG
Front Physiol; 2020; 11():83. PubMed ID: 32116789
[TBL] [Abstract][Full Text] [Related]
18. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease.
Kazim SF; Blanchard J; Dai CL; Tung YC; LaFerla FM; Iqbal IG; Iqbal K
Neurobiol Dis; 2014 Nov; 71():110-30. PubMed ID: 25046994
[TBL] [Abstract][Full Text] [Related]
19. Theranostic F-SLOH mitigates Alzheimer's disease pathology involving TFEB and ameliorates cognitive functions in Alzheimer's disease models.
Iyaswamy A; Wang X; Krishnamoorthi S; Kaliamoorthy V; Sreenivasmurthy SG; Kumar Durairajan SS; Song JX; Tong BC; Zhu Z; Su CF; Liu J; Cheung KH; Lu JH; Tan JQ; Li HW; Wong MS; Li M
Redox Biol; 2022 May; 51():102280. PubMed ID: 35286997
[TBL] [Abstract][Full Text] [Related]
20. Amyloid-β oligomers relate to cognitive decline in Alzheimer's disease.
Jongbloed W; Bruggink KA; Kester MI; Visser PJ; Scheltens P; Blankenstein MA; Verbeek MM; Teunissen CE; Veerhuis R
J Alzheimers Dis; 2015; 45(1):35-43. PubMed ID: 25547634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
